Global Insulin Pumps Market 2023-2029

March 2023 | 90 pages | ID: GFC12C488F7AEN
Gen Consulting Company

Abstracts

Insulin pumps are designed to deliver insulin to patients who have been diagnosed with diabetes. Insulin can be delivered in two ways. It can be administered in a steady and continuous dose, which is also known as basal insulin, or in a surge dose during meals, which is known as bolus insulin. These doses are delivered through a flexible plastic tube called a catheter. The catheter is inserted into the fatty tissue of the skin with the help of a small needle and is held in place with tape. The insulin pump system is designed in a way that mimics the way the body naturally releases insulin. The global insulin pumps market is likely to register a CAGR of over 8.6% with an incremental growth of USD 2.8 billion during the forecast period 2023-2029. The demand for the insulin pumps is primarily driven by the growing prevalence of diabetes among the population. As per the data revealed by the International Diabetes Federation, around 552 million people across the globe are estimated to have diabetes by the year 2030.The demand for the insulin pumps is primarily driven by the growing prevalence of diabetes among the population. As per the data revealed by the International Diabetes Federation, around 552 million people across the globe are estimated to have diabetes by the year 2030.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global insulin pumps market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, disease, end user, and region. The global market for insulin pumps can be segmented by product: consumables, pumps. According to the research, the pumps segment had the largest share in the global insulin pumps market. Insulin pumps market is further segmented by disease: type 1 diabetes, type 2 diabetes. In 2022, the type 1 diabetes segment made up the largest share of revenue generated by the insulin pumps market. Based on end user, the insulin pumps market is segmented into: home healthcare settings, hospital, others. Among these, the hospital segment was accounted for the highest revenue generator in 2022. On the basis of region, the insulin pumps market also can be divided into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America held the highest share in the global insulin pumps market. However, Asia-Pacific is forecast to register the highest CAGR during the forecast period 2023 - 2029.

The pumps market is further segmented into patch pumps, tethered pumps. The latest analysis indicates that the tethered pumps segment occupied the largest share of this market in 2022 and is expected to draw the highest demand in coming years. Furthermore, the patch pumps (by delivery mode) market has been categorized into basal, basal-bolus, bolus. Globally, the basal segment made up the largest share of the insulin pumps market. The patch pumps (by type) market is further divided into disposable, reusable. The reusable segment was the largest contributor to the global insulin pumps market in 2022.

Market Segmentation

By product: consumables, pumps

By disease: type 1 diabetes, type 2 diabetes

By end user: home healthcare settings, hospital, others

By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report also provides analysis of the key companies of the industry and their detailed company profiles including A. Menarini Diagnostics s.r.l, Beijing Maishitong Technology Co., Ltd., CeQur SA, Debiotech S.A., Embecta Corp. (spin-off from BD), EOFlow Co., Ltd., F. Hoffmann-La Roche AG, Insulet Corporation, Kailian Medical Technology (Shanghai) Co., Ltd., MannKind Corporation, Medtronic Plc, Medtrum Technologies Inc., Medzer Ltd., MicroPort Scientific Corporation, Novo Nordisk A/S, Royal Fornia Medical Equipment Co., Ltd., Tandem Diabetes Care, Inc., Terumo Corporation, ViCentra B.V. (Kaleido), Wuxi Apex Medical Co., Ltd., Ypsomed AG, Zhengzhou Phray Technology Co., Ltd., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report

• To analyze and forecast the market size of the global insulin pumps market.
• To classify and forecast the global insulin pumps market based on product, disease, end user, region.
• To identify drivers and challenges for the global insulin pumps market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global insulin pumps market.
• To identify and analyze the profile of leading players operating in the global insulin pumps market.

Why Choose This Report

• Gain a reliable outlook of the global insulin pumps market forecasts from 2023 to 2029 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints

PART 5. MARKET BREAKDOWN BY PRODUCT

Consumables
Pumps

PART 6. MARKET BREAKDOWN BY DISEASE

Type 1 diabetes
Type 2 diabetes

PART 7. MARKET BREAKDOWN BY END USER

Home healthcare settings
Hospital
Others

PART 8. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America

PART 9. KEY COMPANIES

A. Menarini Diagnostics s.r.l
Beijing Maishitong Technology Co., Ltd.
CeQur SA
Debiotech S.A.
Embecta Corp. (spin-off from BD)
EOFlow Co., Ltd.
F. Hoffmann-La Roche AG
Insulet Corporation
Kailian Medical Technology (Shanghai) Co., Ltd.
MannKind Corporation
Medtronic Plc
Medtrum Technologies Inc.
Medzer Ltd.
MicroPort Scientific Corporation
Novo Nordisk A/S
Royal Fornia Medical Equipment Co., Ltd.
Tandem Diabetes Care, Inc.
Terumo Corporation
ViCentra B.V. (Kaleido)
Wuxi Apex Medical Co., Ltd.
Ypsomed AG
Zhengzhou Phray Technology Co., Ltd.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER